Market News AIOpen the app

Alpha Tau Medical Reports Third Quarter 2026 Financial Results and Corporate Update

ResultsRead the original at globenewswire.com
Good for DRTS

Alpha Tau reported all 8 treated patients remain alive, with a 100% response among evaluable patients. FDA approval expands the trial, 48 patients completed another study's enrollment, and $99.8 million in cash supports research, though findings remain early.

DRTS · Alpha Tau Medical

AI read · Good for DRTS

The AI's read

The findings give the treatment a promising early signal, and FDA approval lets researchers test it in more people. Completing enrollment in the pancreatic cancer study and $99.8 million in cash support continued research. The results come from small studies, so they do not yet show how well treatment works for a wider group.

Get alerts for DRTS

Follow Alpha Tau Medical (DRTS) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for DRTS
Free on the App Store and Google Play, or on the web.